Spruce Biosciences, Inc. (SPRB)

Spruce Biosciences' stock has been impacted by several events in the past six months. The FDA granted Breakthrough Therapy Designation to Tralesinidase Alfa (TA-ERT) for Sanfilippo Syndrome Type B, leading to a surge in SPRB's stock. The company secured $50 million in private placement funding, expected to extend its cash runway into Q4 2026. Spruce Biosciences' common stock resumed trading on the Nasdaq Capital Market after a delisting. Spruce Biosciences presented long-term data at the 22nd Annual WORLDSymposium™, highlighting Tralesinidase Alfa's potential. The company secured up to $50 million in growth capital from Avenue Capital. Spruce Biosciences announced the addition of regulatory and clinical development expertise to its leadership team. The company announced data presentations at the 22nd Annual WORLDSymposium™. Keli Walbert was appointed to the company's Board of Directors.

Spruce Biosciences, Inc. does not experience traditional demand seasonality for its products or services. The demand for its investigational therapies is driven by the prevalence of rare diseases and the progress of clinical development and regulatory approvals, rather than seasonal consumer patterns. The company is currently pre-commercial and does not generate revenue from product sales.

Spruce Biosciences, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing therapies for rare endocrine and neurological disorders with unmet medical needs. Their lead product candidate is Tralesinidase Alfa (TA-ERT) for mucopolysaccharidosis Type IIIB (MPS IIIB), which received FDA Breakthrough Therapy Designation and is on track for a BLA filing in the first half of 2026. The company also has Tildacerfont/Cortibon, a companion diagnostic developed in partnership with HMNC Brain Health, SPR202 for CAH and SPR204, a monoclonal antibody antagonist for Post-Bariatric Hypoglycemia, in its pipeline.

Spruce Biosciences, Inc. is headquartered in South San Francisco, California, United States. Its primary operations and market focus are currently within the United States, particularly concerning regulatory approvals and clinical trials.

Spruce Biosciences' brand reputation has seen both positive and negative developments in the past year. The company was recognized as one of the "Best Places to Work in the Bay Area" in both 2024 and 2025. However, the company faced a negative event earlier in 2025 when its stock was delisted from Nasdaq. The subsequent re-listing on Nasdaq and the FDA's Breakthrough Therapy Designation for Tralesinidase Alfa provided a boost to its reputation and investor confidence.

Institutional investors hold a significant portion of Spruce Biosciences' stock, accounting for 91.71% of shares. Major institutional owners include Carlyle Group Inc., Cable Car Capital LLC, Vanguard Group Inc, Ikarian Capital, LLC, UBS Group AG, Lion Point Capital, LP, Sound Income Strategies, LLC, Advisor Group Holdings, Inc., Morgan Stanley, Caldwell Securities, Inc., Armistice Capital LLC, AIGH Capital Management LLC, Worth Venture Partners LLC, Rosalind Advisors Inc., Acadian Asset Management LLC and Superstring Capital Management LP. Notable individual owners include Peter David Boone and CEO Javier Szwarcberg.